公开(公告)号：US12059422B2

公开(公告)日：2024-08-13

申请号：US17845228

申请日：2022-06-21

申请人： MEI Pharma, Inc.

发明人： S. David Brown ,  David J. Matthews

IPC分类号： A61K31/5377 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C12N9/12

CPC分类号： A61K31/5377 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C12N9/1205

摘要： Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

公开(公告)号：US20230372287A1

公开(公告)日：2023-11-23

申请号：US18363328

申请日：2023-08-01

申请人： MEI Pharma, Inc.

发明人： George JEOFFREYS ,  Alison JOHNSON ,  Andrew HEATON ,  Ofir MORENO

IPC分类号： A61K31/353 ,  A61K31/337 ,  A61K31/555 ,  A61K9/00 ,  A61K47/40 ,  A61K9/51 ,  A61K33/243 ,  A61K45/06 ,  C07D311/58

CPC分类号： A61K31/353 ,  A61K31/337 ,  A61K31/555 ,  A61K9/0019 ,  A61K47/40 ,  A61K9/5161 ,  A61K33/243 ,  A61K45/06 ,  C07D311/58

摘要： Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

公开(公告)号：US20230145478A1

公开(公告)日：2023-05-11

申请号：US18154267

申请日：2023-01-13

申请人： MEI Pharma, Inc.

发明人： George JEOFFREYS ,  Alison JOHNSON ,  Andrew HEATON ,  Ofir MORENO

IPC分类号： A61K31/353 ,  A61K31/337 ,  A61K31/555 ,  A61K9/00 ,  A61K47/40 ,  A61K9/51 ,  A61K33/243 ,  A61K45/06 ,  C07D311/58

CPC分类号： A61K31/353 ,  A61K31/337 ,  A61K31/555 ,  A61K9/0019 ,  A61K47/40 ,  A61K9/5161 ,  A61K33/243 ,  A61K45/06 ,  C07D311/58

摘要： Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

公开(公告)号：US20220016082A1

公开(公告)日：2022-01-20

申请号：US17294513

申请日：2019-11-26

申请人： MEI Pharma, Inc.

发明人： Richard GHALIE

IPC分类号： A61K31/4184 ,  A61K31/706 ,  A61P35/02

摘要： Provided herein are methods of treating high and very high risk MDS comprising administering pracinostat and a DNA hypomethylating agent. S

公开(公告)号：US20210196725A1

公开(公告)日：2021-07-01

申请号：US17268050

申请日：2019-08-13

申请人： MEI Pharma, Inc.

发明人： Daniel P. GOLD

IPC分类号： A61K31/5377 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06

摘要： Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the methods comprise treating FL in subjects having disease progression within 24 months of initiating first-line or subsequent immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor.

公开(公告)号：US20210000790A1

公开(公告)日：2021-01-07

申请号：US17023681

申请日：2020-09-17

申请人： MEI Pharma, Inc.

发明人： George JEOFFREYS ,  Alison JOHNSON ,  Andrew HEATON ,  Ofir MORENO

IPC分类号： A61K31/353 ,  A61K31/337 ,  A61K31/555 ,  A61K33/24 ,  A61K9/00 ,  A61K47/40 ,  A61K9/51 ,  A61K45/06 ,  C07D311/58

摘要： Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

公开(公告)号：US10736881B2

公开(公告)日：2020-08-11

申请号：US16221186

申请日：2018-12-14

申请人： MEI Pharma, Inc.

发明人： DiZhong Chen ,  Hong Yan Song ,  Eric T. Sun ,  Niefang Yu ,  Yong Zou

IPC分类号： G01N33/50 ,  G01N33/68 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  C04B35/632 ,  C07D235/06 ,  C07D235/08 ,  C07D235/14 ,  C07D235/18 ,  C07D401/04 ,  A61K31/4184 ,  C07D401/06 ,  C07D401/12 ,  C07D403/02 ,  C07D409/04 ,  C07D413/02 ,  C07D403/06 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5377

摘要： The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).

公开(公告)号：US09981936B2

公开(公告)日：2018-05-29

申请号：US15622569

申请日：2017-06-14

申请人： MEI Pharma, Inc.

发明人： Ofir Moreno

IPC分类号： C07D311/58 ,  A61K31/353 ,  A61K47/40 ,  A61P35/00 ,  A61K9/00 ,  A61K9/51 ,  A61K45/06 ,  A61K31/555 ,  A61K31/337 ,  A61K33/24

CPC分类号： C07D311/58 ,  A61K9/0019 ,  A61K9/5161 ,  A61K31/337 ,  A61K31/353 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K47/40 ,  A61K2300/00

摘要： Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.

公开(公告)号：US09266882B2

公开(公告)日：2016-02-23

申请号：US14517614

申请日：2014-10-17

申请人： MEI Pharma, Inc.

发明人： Ken Chi Lik Lee ,  Eric T. Sun ,  Haishan Wang

IPC分类号： A61K31/44 ,  C07D498/02 ,  C07D491/02 ,  C07D471/04

CPC分类号： C07D471/04 ,  A61K31/44 ,  C07D491/02 ,  C07D498/02 ,  Y02A50/409 ,  Y02A50/411

摘要： The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities (HDAC).

摘要翻译： 本发明涉及作为组蛋白脱乙酰酶抑制剂的异羟肟酸酯化合物。 更具体地，本发明涉及含咪唑并[1,2-a]吡啶的化合物及其制备方法。 这些化合物可用作治疗增殖性疾病的药物以及涉及与组蛋白脱乙酰酶活性（HDAC）的酶有关或与之有关的其它疾病。

公开(公告)号：US20140005194A1

公开(公告)日：2014-01-02

申请号：US14016990

申请日：2013-09-03

申请人： DiZhong CHEN ,  Hong Yan SONG ,  Eric T. SUN ,  Niefang YU ,  Yong ZOU

发明人： DiZhong CHEN ,  Hong Yan SONG ,  Eric T. SUN ,  Niefang YU ,  Yong ZOU

IPC分类号： C07D235/18 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D235/08 ,  C07D235/06 ,  C07D401/04 ,  C07D409/04

CPC分类号： A61K31/4184 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C04B35/632 ,  C07D235/06 ,  C07D235/08 ,  C07D235/14 ,  C07D235/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/02 ,  C07D403/06 ,  C07D409/04 ,  C07D413/02 ,  G01N33/5011 ,  G01N33/6875 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

摘要： The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).

摘要翻译： 本发明涉及作为组蛋白脱乙酰酶抑制剂的异羟肟酸酯化合物。 更具体地说，本发明涉及含苯并咪唑的化合物及其制备方法。 这些化合物可用作治疗增殖性疾病以及涉及组蛋白脱乙酰酶（HDAC）的调节异常或与其相关的其它疾病的药物。